Allstate Corp Takes Position in Henry Schein, Inc. (NASDAQ:HSIC)

Allstate Corp purchased a new position in shares of Henry Schein, Inc. (NASDAQ:HSIC) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 4,022 shares of the company’s stock, valued at approximately $278,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in HSIC. Versant Capital Management Inc lifted its position in Henry Schein by 274.6% in the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock worth $32,000 after buying an additional 335 shares in the last quarter. Venturi Wealth Management LLC raised its holdings in shares of Henry Schein by 3,347.1% during the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the company’s stock worth $41,000 after acquiring an additional 569 shares in the last quarter. Quent Capital LLC boosted its position in Henry Schein by 91.2% during the fourth quarter. Quent Capital LLC now owns 677 shares of the company’s stock valued at $47,000 after purchasing an additional 323 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in Henry Schein by 23.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 759 shares of the company’s stock valued at $52,000 after purchasing an additional 143 shares in the last quarter. Finally, City State Bank acquired a new position in Henry Schein in the 4th quarter worth about $55,000. 96.62% of the stock is owned by hedge funds and other institutional investors.

Henry Schein Stock Performance

HSIC opened at $69.25 on Thursday. Henry Schein, Inc. has a 12-month low of $63.67 and a 12-month high of $82.49. The firm has a market capitalization of $8.60 billion, a P/E ratio of 28.50, a price-to-earnings-growth ratio of 2.13 and a beta of 0.84. The stock’s 50 day moving average price is $74.31 and its two-hundred day moving average price is $72.65. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, February 25th. The company reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.04). Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The company had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.25 billion. During the same period last year, the firm posted $0.66 EPS. The company’s revenue was up 5.8% compared to the same quarter last year. On average, equities analysts forecast that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Insider Activity at Henry Schein

In other Henry Schein news, CEO Bradford C. Connett sold 4,036 shares of the company’s stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total value of $287,161.40. Following the completion of the transaction, the chief executive officer now owns 62,688 shares of the company’s stock, valued at $4,460,251.20. This represents a 6.05 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Philip A. Laskawy sold 2,604 shares of Henry Schein stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total value of $184,988.16. Following the sale, the director now directly owns 24,805 shares in the company, valued at $1,762,147.20. The trade was a 9.50 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts recently commented on HSIC shares. Mizuho initiated coverage on Henry Schein in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $75.00 price target for the company. Bank of America raised shares of Henry Schein from an “underperform” rating to a “buy” rating and boosted their target price for the stock from $69.00 to $84.00 in a research report on Monday, January 6th. Jefferies Financial Group lifted their price objective on shares of Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a research note on Thursday, January 23rd. Barrington Research reiterated an “outperform” rating and issued a $90.00 price objective on shares of Henry Schein in a report on Wednesday, February 26th. Finally, Wells Fargo & Company assumed coverage on Henry Schein in a research report on Friday, February 14th. They issued an “equal weight” rating and a $80.00 price target for the company. Six equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $81.10.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.